ProThera Biologics is a development stage bio-therapeutics Company based in Providence, Rhode Island. The Company was founded in 2002 to focus on the critical role and commercial potential of Inter-alpha Inhibitor Proteins (IAIP) for treating acute life-threatening inflammatory diseases. The discovery reasearch was originated in the basic research laboratories of the co-founders, Yow-Pin Lim, MD/PhD and Douglas C. Hixson, PhD. at Lifespan's Rhode Island Hospital. Currently led by Yow-Pin Lim, M.D./PhD. and Denice Spero, Ph.D., the company is backed by the Slater Technology Fund and has recieved research grants from the Rhode Island Science and Techology Advisory Council as well as continuous funding grants from the National Institutes of Health with multiple Phase I and II Small Business Innovation Research (SBIR) grants over the past 10 years.
ProThera has developed a novel process to purify Inter-alpha Inhibitor Proteins from source materal, and has conducted ground-breaking research into the usage of IAIP to fight systemic inflammation across multiple indication areas.